Seromycin

Cycloserine

Developed to alleviate tuberculosis infections to support bacterial clearance.

Category
Antibiotics
Active ingredient
Cycloserine
Supply
Pharmacy
Route
Oral use
Form
Capsule, hard
Strengths
250mg

Seromycin details

Condition
Tuberculosis
Therapeutic class
Antibiotic
Pharmacological class
Anti-tuberculosis agent
Contraindications
hypersensitivity to cycloserine; epilepsy; severe renal impairment
Minor side effects
headache; dizziness
Moderate side effects
tremor; confusion; vertigo
Dosage forms
Capsule, hard
Administration route
Oral use
Patient summary
Developed to alleviate tuberculosis infections to support bacterial clearance.
Supply category
Pharmacist only, dispensed without a prescription
Manufacturer
Mylan
Onset Time
n/a
Duration
n/a
Storage instructions
Store in a tightly closed container.
Drug interactions
Alcohol; Ethionamide
Pregnancy and breastfeeding
Use during pregnancy only if clearly needed.
Precautions and warnings

monitor for neurological and psychiatric effects; supplementation with vitamin B6 recommended

Serious side effects

seizures, requires immediate medical attention; psychosis, requires immediate medical attention

Mechanism of action

Cycloserine inhibits bacterial cell wall synthesis by acting as an analogue of D-alanine.

Where this medicine is registered

  • Singapore
  • Hong Kong
  • Thailand
  • Malaysia
  • Philippines
  • Indonesia
  • Taiwan
  • South Korea
  • Japan
  • Australia
  • New Zealand
  • UAE
  • South Africa

About Seromycin

Seromycin is a treatment containing cycloserine, used in the management of tuberculosis. Manufactured by Mylan, it is provided as a capsule in the 250mg strength. This medication serves as a therapeutic option for patients requiring this specific active ingredient as part of an ongoing care plan.

Seromycin availability in Asia

Seromycin is registered across 14 markets including Japan, the UAE and Singapore, with availability also in Hong Kong, Thailand and Malaysia. Cycloserine is produced in international manufacturing hubs and serves as an option for patients in regions where access to established medicine can be inconsistent. The treatment is best used under the care of a physician who can monitor progress and individual health needs.